<p>Acumen Pharmaceuticals, Inc.（纳斯达克代码：ABOS - 获取免费报告）首席财务官 Matt Zuga 于 1 月 8 日（星期四）出售了 6,888 股 Acumen Pharmaceuticals 股票。股票以平均价格 1.82 美元出售，总交易额为 12,536.16 美元。出售后，首席财务官持有 209,951 股公司股票，价值 382,110.82 美元。此次交易使其持股减少了 3.18%。该出售在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。</p>
<p>获取 <strong>Acumen Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>MarketBeat 周回顾 – 7/17 - 7/21</li>
</ul>
<p>Matt Zuga 最近还进行了以下交易：</p>
<ul>
<li>1 月 7 日（星期三），Matt Zuga 出售了 5,805 股 Acumen Pharmaceuticals 股票。股票以平均价格 1.99 美元出售，总交易额为 11,551.95 美元。</li>
<li>1 月 6 日（星期二），Matt Zuga 出售了 5,100 股 Acumen Pharmaceuticals 股票。股票以平均价格 1.97 美元出售，总交易额为 10,047.00 美元。</li>
<li>1 月 5 日（星期一），Matt Zuga 出售了 4,000 股 Acumen Pharmaceuticals 股票。股票以平均价格 1.96 美元出售，总价值为 7,840.00 美元。</li>
</ul>
<h2>Acumen Pharmaceuticals 股价下跌 5.0%</h2>
<p>在周一的交易中，ABOS 股价下跌 0.09 美元，跌至 1.72 美元。该股票交易量为 302,203 股，而其平均交易量为 269,914 股。该公司的债务与股本比率为 0.29，速动比率为 6.02，流动比率为 6.02。该公司的 50 日简单移动平均为 1.94 美元，200 日简单移动平均为 1.69 美元。该公司的市值为 1.0418 亿美元，市盈率为-0.77，贝塔值为 0.23。Acumen Pharmaceuticals, Inc.的 1 年最低价为 0.86 美元，1 年最高价为 2.46 美元。</p>
<ul>
<li>Acumen 因阿尔茨海默病研究而飙升……市场预期其股价翻倍</li>
</ul>
<p>Acumen Pharmaceuticals（纳斯达克代码：ABOS - 获取免费报告）最近在 11 月 12 日（星期三）发布了季度财报。公司报告每股收益（EPS）为-0.44 美元，超出分析师一致预期的-0.63 美元，超出幅度为 0.19 美元。整体来看，股票分析师预计 Acumen Pharmaceuticals, Inc.在本年度将发布-1.56 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>多位股票分析师最近对 ABOS 股票发布了报告。Wall Street Zen 在 12 月 21 日（星期日）的研究报告中将 Acumen Pharmaceuticals 的股票评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 14 日（星期二）的研究报告中重申了对 Acumen Pharmaceuticals 股票的 “卖出（d-）” 评级。最后，美国银行在 11 月 18 日（星期二）的报告中将 Acumen Pharmaceuticals 的目标股价从 9.00 美元下调至 8.00 美元，并对该股票给予 “买入” 评级。四位研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat 的数据，Acumen Pharmaceuticals 目前的平均评级为 “适度买入”，平均目标价格为 6.75 美元。</p>
<p><strong>阅读我们关于 ABOS 的最新研究报告</strong></p>
<h2>Acumen Pharmaceuticals 的机构交易</h2>
<p>多家机构投资者最近对 ABOS 的持仓进行了调整。Y Intercept Hong Kong Ltd 在第二季度收购了 Acumen Pharmaceuticals 的新头寸，价值约 291,000 美元。SG Americas Securities LLC 在第三季度收购了 Acumen Pharmaceuticals 的新股份，价值约 691,000 美元。Jacobs Levy Equity Management Inc.在第三季度购买了 Acumen Pharmaceuticals 的新股份，价值约 27,000 美元。Susquehanna International Group LLP 在第三季度将其在 Acumen Pharmaceuticals 的持仓提高了 26.5%。Susquehanna International Group LLP 目前持有 214,440 股公司股票，价值 367,000 美元，此前在上个季度又购买了 44,902 股。最后，美国银行在第三季度将其在 Acumen Pharmaceuticals 的持仓提高了 45.4%。美国银行目前持有 213,729 股公司股票，价值 365,000 美元，此前在上个季度又购买了 66,720 股。机构投资者和对冲基金持有公司 71.01% 的股票。</p>
<h2>关于 Acumen Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Acumen Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于针对神经退行性疾病的口服小分子疗法的发现和开发。该公司利用一种集成了化学蛋白质组学、高通量筛选和计算化学的专有药物发现平台，旨在识别和优化选择性调节病理性蛋白质聚集的化合物。其方法旨在解决阿尔茨海默病、帕金森病、肌萎缩侧索硬化症及相关蛋白病等疾病的基础生物学问题。</p>
<p>该公司的产品管线包括多个处于不同临床前和早期临床开发阶段的主要候选药物。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票超过 Acumen Pharmaceuticals</li>
<li>崩盘前一个月</li>
<li>家族信托如何帮助保护您的财富</li>
<li>特朗普的手写信将震惊他的反对者</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Acumen Pharmaceuticals 吗？</h2>
<p>在您考虑 Acumen Pharmaceuticals 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Acumen Pharmaceuticals 并不在名单上。</p>
<p>虽然 Acumen Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ABOS

<p>Acumen Pharmaceuticals 首席财务官 Matt Zuga 以每股 1.82 美元的价格出售了 6,888 股，总计 12,536.16 美元，代表其持股减少了 3.18%。出售后，他持有 209,951 股，估值约为 382,110.82 美元。此交易已向美国证券交易委员会（SEC）披露。Zuga 本周早些时候还出售了其他股份。Acumen 的股票最近下跌了 5%，至 1.72 美元，市值为 1.0418 亿美元，市盈率为 -0.77。分析师对该股票的评级不一，平均目标价格为 6.75 美元</p>

<p>Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of Acumen Pharmaceuticals stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $1.82, for a total transaction of $12,536.16. Following the sale, the chief financial officer owned 209,951 shares of the company's stock, valued at $382,110.82. The trade was a 3.18% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals, Inc.（纳斯达克代码：ABOS - 获取免费报告）首席财务官 Matt Zuga 于 1 月 8 日（星期四）出售了 6,888 股 Acumen Pharmaceuticals 股票。股票以平均价格 1.82 美元出售，总交易额为 12,536.16 美元。出售后，首席财务官持有 209,951 股公司股票，价值 382,110.82 美元。此次交易使其持股减少了 3.18%。该出售在向证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。</p>
</div><p>Get <strong>Acumen Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Acumen Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>MarketBeat Week in Review – 7/17 - 7/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 7/17 - 7/21</li>
</ul>
</div><p>Matt Zuga also recently made the following trade(s):</p>
<div class="lb-trans"><p>Matt Zuga 最近还进行了以下交易：</p>
</div><ul>
<li>On Wednesday, January 7th, Matt Zuga sold 5,805 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.99, for a total transaction of $11,551.95.</li>
<li>On Tuesday, January 6th, Matt Zuga sold 5,100 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total transaction of $10,047.00.</li>
<li>On Monday, January 5th, Matt Zuga sold 4,000 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.96, for a total value of $7,840.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>1 月 7 日（星期三），Matt Zuga 出售了 5,805 股 Acumen Pharmaceuticals 股票。股票以平均价格 1.99 美元出售，总交易额为 11,551.95 美元。</li>
<li>1 月 6 日（星期二），Matt Zuga 出售了 5,100 股 Acumen Pharmaceuticals 股票。股票以平均价格 1.97 美元出售，总交易额为 10,047.00 美元。</li>
<li>1 月 5 日（星期一），Matt Zuga 出售了 4,000 股 Acumen Pharmaceuticals 股票。股票以平均价格 1.96 美元出售，总价值为 7,840.00 美元。</li>
</ul>
</div><h2>Acumen Pharmaceuticals Trading Down 5.0%</h2>
<div class="lb-trans"><h2>Acumen Pharmaceuticals 股价下跌 5.0%</h2>
</div><p>ABOS traded down $0.09 during trading on Monday, hitting $1.72. 302,203 shares of the stock were exchanged, compared to its average volume of 269,914. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. The firm has a 50 day simple moving average of $1.94 and a 200 day simple moving average of $1.69. The firm has a market cap of $104.18 million, a price-to-earnings ratio of -0.77 and a beta of 0.23. Acumen Pharmaceuticals, Inc. has a 1 year low of $0.86 and a 1 year high of $2.46.</p>
<div class="lb-trans"><p>在周一的交易中，ABOS 股价下跌 0.09 美元，跌至 1.72 美元。该股票交易量为 302,203 股，而其平均交易量为 269,914 股。该公司的债务与股本比率为 0.29，速动比率为 6.02，流动比率为 6.02。该公司的 50 日简单移动平均为 1.94 美元，200 日简单移动平均为 1.69 美元。该公司的市值为 1.0418 亿美元，市盈率为-0.77，贝塔值为 0.23。Acumen Pharmaceuticals, Inc.的 1 年最低价为 0.86 美元，1 年最高价为 2.46 美元。</p>
</div><ul>
<li>Acumen Soars on Alzheimer's Study...Street Sees It Doubling</li>
</ul>
<div class="lb-trans"><ul>
<li>Acumen 因阿尔茨海默病研究而飙升……市场预期其股价翻倍</li>
</ul>
</div><p>Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.19. As a group, equities analysts expect that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current year.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals（纳斯达克代码：ABOS - 获取免费报告）最近在 11 月 12 日（星期三）发布了季度财报。公司报告每股收益（EPS）为-0.44 美元，超出分析师一致预期的-0.63 美元，超出幅度为 0.19 美元。整体来看，股票分析师预计 Acumen Pharmaceuticals, Inc.在本年度将发布-1.56 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities analysts have recently issued reports on ABOS shares. Wall Street Zen upgraded shares of Acumen Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, December 21st. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Acumen Pharmaceuticals in a research report on Tuesday, October 14th. Finally, Bank of America cut their price target on Acumen Pharmaceuticals from $9.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, November 18th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Acumen Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $6.75.</p>
<div class="lb-trans"><p>多位股票分析师最近对 ABOS 股票发布了报告。Wall Street Zen 在 12 月 21 日（星期日）的研究报告中将 Acumen Pharmaceuticals 的股票评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 14 日（星期二）的研究报告中重申了对 Acumen Pharmaceuticals 股票的 “卖出（d-）” 评级。最后，美国银行在 11 月 18 日（星期二）的报告中将 Acumen Pharmaceuticals 的目标股价从 9.00 美元下调至 8.00 美元，并对该股票给予 “买入” 评级。四位研究分析师对该股票给予了 “买入” 评级，一位分析师给予了 “卖出” 评级。根据 MarketBeat 的数据，Acumen Pharmaceuticals 目前的平均评级为 “适度买入”，平均目标价格为 6.75 美元。</p>
</div><p><strong>Read Our Latest Research Report on ABOS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ABOS 的最新研究报告</strong></p>
</div><h2>Institutional Trading of Acumen Pharmaceuticals</h2>
<div class="lb-trans"><h2>Acumen Pharmaceuticals 的机构交易</h2>
</div><p>A number of institutional investors have recently made changes to their positions in ABOS. Y Intercept Hong Kong Ltd acquired a new position in Acumen Pharmaceuticals during the 2nd quarter valued at about $291,000. SG Americas Securities LLC acquired a new stake in Acumen Pharmaceuticals in the third quarter worth about $691,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Acumen Pharmaceuticals during the third quarter worth about $27,000. Susquehanna International Group LLP raised its position in shares of Acumen Pharmaceuticals by 26.5% in the 3rd quarter. Susquehanna International Group LLP now owns 214,440 shares of the company's stock valued at $367,000 after purchasing an additional 44,902 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Acumen Pharmaceuticals by 45.4% in the 3rd quarter. Bank of America Corp DE now owns 213,729 shares of the company's stock valued at $365,000 after purchasing an additional 66,720 shares during the last quarter. Institutional investors and hedge funds own 71.01% of the company's stock.</p>
<div class="lb-trans"><p>多家机构投资者最近对 ABOS 的持仓进行了调整。Y Intercept Hong Kong Ltd 在第二季度收购了 Acumen Pharmaceuticals 的新头寸，价值约 291,000 美元。SG Americas Securities LLC 在第三季度收购了 Acumen Pharmaceuticals 的新股份，价值约 691,000 美元。Jacobs Levy Equity Management Inc.在第三季度购买了 Acumen Pharmaceuticals 的新股份，价值约 27,000 美元。Susquehanna International Group LLP 在第三季度将其在 Acumen Pharmaceuticals 的持仓提高了 26.5%。Susquehanna International Group LLP 目前持有 214,440 股公司股票，价值 367,000 美元，此前在上个季度又购买了 44,902 股。最后，美国银行在第三季度将其在 Acumen Pharmaceuticals 的持仓提高了 45.4%。美国银行目前持有 213,729 股公司股票，价值 365,000 美元，此前在上个季度又购买了 66,720 股。机构投资者和对冲基金持有公司 71.01% 的股票。</p>
</div><h2>About Acumen Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Acumen Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于针对神经退行性疾病的口服小分子疗法的发现和开发。该公司利用一种集成了化学蛋白质组学、高通量筛选和计算化学的专有药物发现平台，旨在识别和优化选择性调节病理性蛋白质聚集的化合物。其方法旨在解决阿尔茨海默病、帕金森病、肌萎缩侧索硬化症及相关蛋白病等疾病的基础生物学问题。</p>
</div><p>The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同临床前和早期临床开发阶段的主要候选药物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Acumen Pharmaceuticals</li>
<li>A month before the crash</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Trump’s Hand-Written Letter Will Shock his Haters</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Acumen Pharmaceuticals</li>
<li>崩盘前一个月</li>
<li>家族信托如何帮助保护您的财富</li>
<li>特朗普的手写信将震惊他的反对者</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ABOS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Acumen Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Acumen Pharmaceuticals 吗？</h2>
</div><p>Before you consider Acumen Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Acumen Pharmaceuticals 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acumen Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Acumen Pharmaceuticals 并不在名单上。</p>
</div><p>While Acumen Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Acumen Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内部人士出售：Acumen Pharmaceuticals（纳斯达克股票代码：ABOS）的首席财务官出售了 6,888 股股票